Scientists Review Can-Fite Drugs' Therapeutic Effects on Heart Diseases

Can-Fite BioPharma Ltd., a biotechnology company based in RAMAT-GAN, Israel, recently announced that a scientific review has been published in the International Journal of Molecular Sciences. This review, authored by independent scientists, compiles findings from over 50 publications worldwide and highlights the beneficial effects of Can-Fite’s drugs piclidenoson and namodenoson on heart diseases.

The review details that in pre-clinical in vivo studies, both piclidenoson and namodenoson have shown positive outcomes in addressing cardiac ischemia, protecting against ischemic/reperfusion injury, reducing infarct size, improving contractile function, and mitigating cardiac hypertrophy, fibrosis, and myocardial dysfunction. Dr. Pnina Fishman, Can-Fite's Chief Scientific Officer and Executive Chairperson, expressed enthusiasm about these findings, noting that the cardio-protective effects of these drug candidates could significantly impact a broad range of heart diseases. She also highlighted the good safety profile observed in over 1,600 patients during clinical development for conditions such as psoriasis, liver cancer, and Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Can-Fite is actively progressing with several clinical studies. The company is preparing to commence a Phase 3 clinical trial for psoriasis, continues to enroll patients in a Phase 3 study for advanced liver cancer, and is conducting a Phase 2b study for MASH. Additionally, they are planning to start a Phase 2a clinical study in pancreatic cancer soon.

Can-Fite BioPharma Ltd. is an advanced clinical-stage drug development company focusing on treatments for cancer, liver, and inflammatory diseases. Their lead drug candidate, Piclidenoson, has recently reported promising results in a Phase III trial for psoriasis and is gearing up for a pivotal Phase III trial. Namodenoson, another prominent drug in their pipeline, is currently being evaluated in a Phase IIb trial for MASH, a Phase III trial for hepatocellular carcinoma (HCC), and there are plans for a Phase IIa study in pancreatic cancer. Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second-line treatment for HCC by the U.S. Food and Drug Administration. This drug has also shown potential for treating other cancers, including colon, prostate, and melanoma. Can-Fite’s third drug candidate, CF602, has demonstrated efficacy in treating erectile dysfunction. Collectively, these drugs have established a robust safety profile in clinical studies involving over 1,600 patients.

The company remains committed to advancing its product candidates through rigorous preclinical and clinical trials while ensuring regulatory compliance and seeking necessary approvals. Can-Fite aims to establish and maintain strategic partnerships to enhance the development and commercialization of their drugs. The company is also focused on safeguarding its intellectual property rights to support its business operations and product candidates.

Can-Fite acknowledges the inherent risks and uncertainties associated with drug development and the broader business environment, including financial stability, regulatory hurdles, market acceptance, and competitive pressures. They also recognize the potential impacts of global events such as the COVID-19 pandemic and geopolitical conflicts on their operations.

In conclusion, Can-Fite BioPharma Ltd. continues to make significant strides in developing treatments for various severe health conditions, backed by promising scientific research and a dedication to rigorous clinical testing. The company remains optimistic about the future prospects of their drug candidates and their potential to address unmet medical needs across multiple therapeutic areas.